(1) Background: Gastric cancer (GC) remains a major global health challenge due to its high heterogeneity and aggressive progression. The discovery of novel bioactive molecules with anticancer properties has, therefore, become a critical research focus. In this study, we synthesized and characterized 4,4′-(5,8-dioxa-2,11-diazadodecane-1,11-diene-1,12-diyl)diphenol (DODP) and evaluated its anticancer potential using molecular docking, bioinformatics, and experimental analyses. (2) Methods: The chemical structure of DODP was confirmed through ¹H and ¹³C NMR spectroscopy. Molecular docking was conducted to examine the interaction of DODP with apoptosis and cell cycle-related proteins (TP53, MDM2, and MYC) and the immune checkpoint marker CD274 (PD-L1). Cytotoxicity against AGS GC cells was determined using the MTT assay at concentrations ranging from 0.01 to 50 µM, and gene expression alterations were analyzed by quantitative polymerase chain reaction (qPCR) and bioinformatics evaluation. (3) Results: NMR data verified the successful synthesis of DODP. The docking results indicated strong binding affinity, especially with TP53 and CD274. DODP showed notable cytotoxicity after 72 h of exposure and induced upregulation of TP53, MYC, and CD274 and downregulation of MDM2 in AGS cells. Although the patterns were consistent with cell-based and bioinformatic analyses, significant discriminatory ability in blood samples was observed only for MYC (AUC = 0.651; p = 0.044). (4) Conclusions: DODP influenced apoptosis-associated transcriptional responses in GC, offering early mechanistic evidence that should be evaluated in more comprehensive biological models.

BACKGROUND Delayed graft function remains a common and clinically relevant complication following kidney transplantation, yet reliable early prediction tools are limited. This small-scale, retrospective, exploratory study investigated whether routine hematologic inflammatory indices, such as the systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and prognostic inflammatory value (PIV), when considered alongside donor-recipient demographic characteristics, predict the need for early posttransplant dialysis. MATERIAL AND METHODS Retrospective analysis of 33 cadaveric kidney transplant recipients was performed. Catorigization into dialysis (n=14) and non-dialysis (n=19) groups was based on early posttransplant dialysis requirement. SII, SIRI, and PIV were calculated from pretransplant laboratory parameters. Given the exploratory study design, analyses were primarily descriptive, supported by univariate comparisons and logistic regression with bootstrap resampling. RESULTS Recipients requiring dialysis tended to receive kidneys from older donors, although this did not reach statistical significance. Monocyte count was significantly lower in the dialysis group (P=0.032). Inflammatory indices, including SII, SIRI, and PIV, showed no significant differences (P>0.05). Logistic regression analyses did not identify SII, SIRI, or PIV as independent dialysis predictors. However, bootstrap resampling showed consistent, although non-significant, directional trends, suggesting higher donor age and inflammatory burden among recipients requiring dialysis. CONCLUSIONS This study provides preliminary insights into the potential role of combined hematologic inflammatory indices in the context of delayed graft function, underscoring the need for larger, prospective studies to clarify whether inflammatory burden and donor-related factors can be integrated into clinically useful prediction models for early dialysis after kidney transplantation.

Objective: We aim to present the outcomes of the Laser Hemorrhoidoplasty (LHP) procedure performed in our clinic. Methods: In this retrospective study, we analyzed the outcomes of LHP performed on 112 patients in our clinic over a 24-month period. Patients were scheduled for follow-up visits at three weeks post-surgery, followed by subsequent follow-ups at three and six-month intervals. Results: Of the 112 patients, 73 (65.17%) were male, and 39 (34.82%) were female. The mean age was 52.6 years (range: 20-65). The mean operation duration was 18.3 minutes (range: 12-25). Seventy patients were classified as grade 2, while 42 patients were classified as grade 3. The mean hospital stay was 1.16 days. While 5 of 70 patients with Grade 2 hemorrhoids could not be followed up after surgery, 24 were followed for 6 months and 41 for 1 year. One (1.42%) patient who attended the 1-year follow-up showed recurrence. Four patients (9.52%) showed recurrence. One patient with grade 3 hemorrhoids experienced postoperative bleeding lasting one week, requiring erythrocyte suspension transfusion. Another patient with grade 3 hemorrhoids developed a hematoma, which resolved with conservative treatment. Eight patients (7.14%) with grade 3 hemorrhoids developed postoperative edema, all of whom improved with conservative treatment. Pain, evaluated by the Visual Analog Scale, was measured as 2.03 on the first postoperative day and 1.49 on the second postoperative day. Conclusion: LH treatment has been found to be a successful alternative treatment option for Grade 2 and Grade 3 diseases. It is emphasized that patient selection is crucial in LH treatment.

Gastric cancer remains a major cause of cancer-related mortality worldwide, highlighting the need for an improved understanding of its molecular mechanisms. Purinergic and glutamatergic signaling pathways, immune checkpoint molecules, and oxidative stress are thought to contribute to tumor biology; however, their combined evaluation in gastric cancer is limited. Methods: Gene expression levels of glutamate receptor ionotropic N-Methyl-D-aspartate 2A (GRIN2A), purinergic receptor P2X1 (P2RX1), and programmed death-ligand 1 (PD-L1/CD274) were analyzed using real-time PCR, while serum protein levels were determined by ELISA. Total antioxidant status (TAS) and total oxidant status (TOS) were also measured to assess systemic oxidative balance. Results: Gene expression analysis revealed an increased expression trend for P2RX1 in the gastric cancer group compared with healthy controls, whereas GRIN2A and CD274 (PD-L1) expression levels showed numerical decreases. Serum concentrations of GRIN2A and PD-L1, as well as TAS and TOS levels, were numerically higher in patients with gastric cancer; however, none of these differences reached statistical significance (p > 0.05). Likewise, serum P2RX1 levels did not differ significantly between groups. Receiver operating characteristic (ROC) analysis demonstrated area under the curve (AUC) values close to 0.5 for all evaluated parameters, indicating limited discriminatory and diagnostic performance. Conclusions: These findings suggest that these molecular markers may reflect disease-related biological alterations rather than serve as independent circulating diagnostic biomarkers in gastric cancer.

The VEGFA and VEGFR2/KDR signaling pathway is a major regulator of tumor angiogenesis and colorectal cancer (CRC) progression. This study investigated the anticancer effects of Compound 107 using integrated clinical, in vitro, and in silico approaches. VEGFA and KDR expression was evaluated in paired colorectal tumor and adjacent non-neoplastic tissues, while molecular docking and ADMET analyses were performed to characterize Compound 107. Its effects on viability, apoptosis, cell-cycle distribution, VEGFA/KDR gene expression, and VEGFA and VEGFR2 protein levels were assessed in HT-29 cells. VEGFA and KDR expression was significantly increased in CRC tissues by 1.98- and 2.02-fold, respectively (both p < 0.001), accompanied by increased protein immunoreactivity (both p < 0.0001). Compound 107 showed favorable predicted binding to VEGFA (−8.60 kcal/mol) and VEGFR2 (−8.30 kcal/mol), although ADMET analysis indicated limitations related to pharmacokinetic and toxicity profiles. Compound 107 reduced MTT-based metabolic viability in a concentration- and time-dependent manner, increased early apoptosis, decreased the G0/G1 population, and increased the S-phase population. Moreover, VEGFA and KDR gene expression and corresponding protein fluorescence intensities were significantly reduced following treatment. Collectively, Compound 107 reduced metabolic viability and increased early apoptosis, accompanied by reduced VEGFA and KDR expression in HT-29 cells. These findings indicate an association between the cellular effects of Compound 107 and changes in VEGFA/VEGFR2-related molecular markers; however, they do not demonstrate direct inhibition of the VEGFA/VEGFR2 signaling pathway. Further mechanistic studies are required to clarify this relationship.